Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 11, 2026
Why Is Cardinal Infrastructure Group (CDNL) Stock Down -26.25% Today?

Why Is Cardinal Infrastructure Group (CDNL) Stock Down -26.25% Today?

Key Takeaways

  • Cardinal Infrastructure Group shares plunged approximately 26.25% on Tuesday, falling from a prior close of $60.00 to around $44.25 in intraday trading.
  • The primary catalyst was a significant second-quarter earnings miss, with GAAP EPS of $0.26 coming in well below consensus estimates of roughly $0.47.
  • Despite reporting record quarterly revenue of $226.9 million (up 114% year-over-year and beating estimates by nearly $48 million), margin compression across the business spooked investors.
  • Adjusted gross profit margin contracted sharply to 15.9% from 21.3% a year ago, while adjusted EBITDA margin fell to 12.4% from 18.6%, driven by elevated subcontractor costs, weather disruptions, and accelerated corporate spending.
  • The company also announced the acquisition of Allied Paving for approximately $120 million and raised full-year revenue guidance to $880–$900 million, though margin guidance was cut.
  • Traders are now watching for analyst rating revisions, management's execution on margin recovery, and how the Allied Paving integration unfolds in the coming quarters.

Opening Summary

Shares of CDNL, Cardinal Infrastructure Group Inc. — one of the Southeast's fastest-growing full-service infrastructure providers specializing in civil and site-development solutions — suffered a dramatic sell-off on Tuesday following the release of second-quarter 2026 results. The stock tumbled roughly 26.25% to approximately $44.25, down sharply from Monday's closing price of $60.00. While the company delivered record revenue and raised its full-year top-line forecast, a deeper-than-expected earnings miss and pronounced margin deterioration across the business triggered an aggressive repricing by the market.

Q2 Earnings Miss Overshadows Revenue Surge

Cardinal Infrastructure Group reported Q2 2026 GAAP diluted earnings per share of $0.26, missing consensus analyst estimates of approximately $0.47 by a wide margin of roughly $0.21. The magnitude of the earnings shortfall grabbed the market's attention immediately, as it signaled that the company's rapid growth trajectory was coming at a steeper cost than Wall Street had modeled.

On the revenue side, the picture was starkly different. Cardinal posted quarterly revenue of $226.9 million, a 113.8% year-over-year increase that handily beat the consensus estimate of roughly $179.6 million by approximately $47.3 million. Organic growth, which excludes contributions from recent acquisitions, came in at 64%, underscoring robust underlying demand across the company's residential, commercial, industrial, and municipal project portfolio.

The company also raised its full-year 2026 revenue guidance to a range of $880 million to $900 million, well above the prior consensus forecast near $717.7 million. However, the revenue beat and raised guidance were not enough to offset the margin concerns that accompanied the report.

Margin Compression and Rising Costs Trigger Alarm

The most sobering element of the Q2 report was the sharp erosion in profitability margins. Gross profit margin fell to 10.8% from 13.9% in the year-ago quarter. On an adjusted basis, which excludes depreciation and amortization, adjusted gross profit margin dropped to 15.9% from 21.3%. Adjusted EBITDA margin similarly compressed to 12.4% from 18.6% a year earlier.

CEO Jeremy Spivey addressed the issue directly: “Keeping pace with this level of customer demand, and investing to capture the opportunity it represents, cost more than we expected this quarter, resulting in margins below plan.” Management cited elevated subcontracted labor and equipment rental costs in developing markets, an intentional shift toward a less residential-weighted project mix, and intense weather-related disruptions across parts of the Southeast as key drags on profitability.

Additionally, the company signaled that accelerated investment in corporate infrastructure would reshape its 2026 margin outlook, even as it maintained conviction in medium-term margin expansion. The updated full-year guidance calls for an adjusted EBITDA margin of 16% to 18%, a meaningful step down from what many analysts had been modeling based on prior quarterly trends.

Allied Paving Acquisition Adds Strategic Breadth

Alongside the earnings release, Cardinal announced the acquisition of Allied Paving Contractors, an Atlanta-based paving and heavy site construction contractor, in a deal valued at approximately $120 million, split between roughly $62 million in cash and $58 million in stock. Allied generates approximately $108 million in annual revenue at a 20.3% adjusted EBITDA margin, and the transaction price implies a highly accretive 5.5x adjusted EBITDA multiple.

Strategically, the acquisition brings paving capabilities in-house in the Atlanta market and is expected to support margin capture and shorter project timelines across the region. It marks Cardinal's third acquisition of 2026 and ninth since 2021. The deal is expected to close in early October, subject to customary conditions.

Market Context and Trading Activity

Tuesday's sell-off was accompanied by significantly elevated trading volume, reflecting intense institutional repositioning around the earnings release. The magnitude of the decline — erasing roughly a quarter of the company's market value in a single session — signals that investors were caught off guard by the margin deterioration, particularly given that Cardinal had beaten earnings estimates in the prior quarter.

The stock's plunge pushed CDNL well below its 50-day moving average, which had been near $69.35 before the report. The reaction also reflects broader market sensitivity to profitability metrics among high-growth industrial names, where investors have grown increasingly discerning about the trade-off between top-line expansion and bottom-line performance. Notably, Cardinal's backlog swelled to $866 million, up 35% year-over-year, offering a strong demand signal that partially cushioned sentiment but could not offset near-term margin fears.

What Comes Next for CDNL

Looking ahead, the key question for CDNL is whether management can execute on margin recovery while sustaining the remarkable organic growth trajectory. The raised revenue guidance of $880–$900 million implies continued strong demand, but the adjusted EBITDA margin target of 16–18% will be closely scrutinized in upcoming quarters. Analysts currently carry a median price target of $63.00, with a high estimate of $80.00 from Oppenheimer and a low of $35.00 from DA Davidson, reflecting a wide dispersion of views on the company's path forward.

Investors will also monitor the integration of Allied Paving and its contribution to consolidated margins, as well as any improvement in subcontractor cost pressures as project deployment schedules progress through the second half of 2026. Risks include continued weather-related disruptions, persistent labor and equipment cost inflation, and the possibility that rapid growth continues to outstrip the company's operational infrastructure.

Trending AI Robots

In volatile sessions like today's, many traders turn to systematic, data-driven strategies to navigate market swings. Tickeron's Trending AI Robots page features a curated selection of hundreds of AI-powered trading bots that cover thousands of tickers, each tailored to specific strategies, timeframes, and performance objectives. Only the strongest-performing bots under current market conditions are highlighted, giving traders a real-time view into which algorithmic approaches are delivering results. Explore the Trending AI Robots to see which strategies are resonating in today's market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CDNL

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


CDNL sees its Stochastic Oscillator climbs out of oversold territory

On August 03, 2026, the Stochastic Oscillator for CDNL moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 7 instances where the indicator left the oversold zone. In of the 7 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 07, 2026. You may want to consider a long position or call options on CDNL as a result. In of 8 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CDNL advanced for three days, in of 35 cases, the price rose further within the following month. The odds of a continued upward trend are .

CDNL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CDNL turned negative on July 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 5 similar instances when the indicator turned negative. In of the 5 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDNL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CDNL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.949) is normal, around the industry mean (17.280). P/E Ratio (44.483) is within average values for comparable stocks, (223.868). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.129). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (1.694) is also within normal values, averaging (3.030).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDNL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock worse than average.

Notable companies

The most notable companies in this group are MasTec (NYSE:MTZ).

Industry description

Engineering & Construction includes companies that engage in non-residential construction and contract services, including ventilation, heating and air conditioning (HVAC) services. The level/value of construction & engineering activity is one of the potentially relevant indicators of the health of businesses, and hence of the overall economy. Some of the large-cap U.S. companies in this industry include Jacobs Engineering Group Inc,, AECOM and Quanta Services, Inc.

Market Cap

The average market capitalization across the Engineering & Construction Industry is 8.42B. The market cap for tickers in the group ranges from 15.66K to 14.67T. WKAPF holds the highest valuation in this group at 14.67T. The lowest valued company is CIPI at 15.66K.

High and low price notable news

The average weekly price growth across all stocks in the Engineering & Construction Industry was -0%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 0%. BWMN experienced the highest price growth at 55%, while RITR experienced the biggest fall at -51%.

Volume

The average weekly volume growth across all stocks in the Engineering & Construction Industry was -95%. For the same stocks of the Industry, the average monthly volume growth was -1% and the average quarterly volume growth was 24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 56
Price Growth Rating: 59
SMR Rating: 72
Profit Risk Rating: 71
Seasonality Score: -24 (-100 ... +100)
View a ticker or compare two or three
CDNL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry EngineeringConstruction

Profile
Details
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.